Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Abidemi Adeniji"'
Autor:
Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, Jaafar Bennouna, Mustafa Erman, Enriqueta Felip, Dolores Isla, Hye Ryun Kim, Sang-We Kim, Jeannick Madelaine, Olivier Molinier, Mustafa Özgüroğlu, Delvys Rodríguez Abreu, Abidemi Adeniji, Robert M. Lorence, Isabelle Voccia, Michael J. Chisamore, Jonathan W. Riess
Publikováno v:
Scientia
LUNG CANCER
LUNG CANCER, 2022, 166, pp.107-113. ⟨10.1016/j.lungcan.2022.01.023⟩
LUNG CANCER
LUNG CANCER, 2022, 166, pp.107-113. ⟨10.1016/j.lungcan.2022.01.023⟩
Afatinib; Carcinoma, Squamous Cell; Pembrolizumab Afatinib; Carcinoma de células escamosas; Pembrolizumab Afatinib; Carcinoma de cèl·lules escamoses; Pembrolizumab Introduction Afatinib and pembrolizumab have separately shown survival benefit in p
Publikováno v:
Pharmaceutical Statistics. 17:74-89
The product limit or Kaplan-Meier (KM) estimator is commonly used to estimate the survival function in the presence of incomplete time to event. Application of this method assumes inherently that the occurrence of an event is known with certainty. Ho
Autor:
Abidemi Adeniji, Gavin Giovannoni, Per Soelberg Sørensen, Peter Rieckmann, Fernando Dangond, Stuart D. Cook, Giancarlo Comi, Kottil Rammohan, Patrick Vermersch
Publikováno v:
Giovannoni, G, Soelberg Sorensen, P, Cook, S, Rammohan, K, Rieckmann, P, Comi, G, Dangond, F, Adeniji, A K & Vermersch, P 2018, ' Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis : Results from the randomized extension trial of the CLARITY study ', Multiple Sclerosis Journal, vol. 24, no. 12, pp. 1594-1604 . https://doi.org/10.1177/1352458517727603
Background:In the 2-year CLARITY study, cladribine tablets significantly improved clinical and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing–remitting multiple sclerosis (MS).Objective:To assess the safety and ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a20d7dc5bfcd38afab5b85f724ed31c
https://curis.ku.dk/ws/files/216467861/1352458517727603.pdf
https://curis.ku.dk/ws/files/216467861/1352458517727603.pdf
Autor:
Myrlene A. Staten, Anita P. Courcoulas, Gregory Dakin, David R. Flum, Mark D. Smith, William C. Chapman, Bruce M. Wolfe, Carol A. McCloskey, Emma J. Patterson, Abdus S. Wahed, Abidemi Adeniji, James E. Mitchell, Alfons Pomp
Publikováno v:
Surgery for Obesity and Related Diseases. 11:313-320
Anastomotic leak is one of the most serious complications after Roux-en-Y gastric bypass (RYGB). Our objective was to examine the relationship between technical factors and incidence of clinically relevant anastomotic leak after RYGB in longitudinal
Publikováno v:
Journal of Applied Statistics. 41:60-72
Empirical distribution function (EDF) is a commonly used estimator of population cumulative distribution function. Survival function is estimated as the complement of EDF. However, clinical diagnosis of an event is often subjected to misclassificatio
Autor:
Steven H. Belle, Walter J. Pories, Hallie Ericson, Kathy Lancaster, Bruce M. Wolfe, William Gourash, Faith Ebel, Laurie Koozer Iacono, Anne MacDougall, Jessie K. Eagleton, Chelsea Cassady, Abidemi Adeniji
Publikováno v:
Surgery for Obesity and Related Diseases. 9:514-519
Background Retaining participants in observational longitudinal studies after bariatric surgery is difficult yet critical because the retention rate affects interpretation and generalizability of results. Strategies for keeping participants involved
Publikováno v:
Journal of Modern Applied Statistical Methods. 11:218-232
Clustered data, multiple observations collected on the same experimental unit, is common in epidemiological studies. Bivariate outcome data is often the result of interest in two correlated response variables. An efficient method is presented for dea
Autor:
Patrick Vermersch, Per Soelberg-Sorensen, Gavin Giovannoni, Stuart D. Cook, Giancarlo Comi, Fernando Dangond, Christine Hicking, Abidemi Adeniji, Kottil Rammohan, Peter Rieckmann
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 88:A48.2-A48
Background In CLARITY, cladribine tablets (CT) significantly reduced relapse rates in patients with relapsing multiple sclerosis. CLARITY Extension (EXT) compared the effects of 2 years’ additional CT treatment vs no additional treatment. Objective
Publikováno v:
Revue Neurologique. 173:S115
Introduction L’etude CLARITY chez des patients atteints de SEP recurrente a montre que Cladribine Comprimes (CC) administree annuellement pendant 2 ans apportait une amelioration clinique significative vs. placebo (PBO). Objectifs Evaluer l’effic
Autor:
Bradley D. Vince, Abidemi Adeniji, Robert R. Riesenberg, Fenglei Huang, Lynn R. Webster, Michael J. Schobelock, David Joseph, Mabrouk Elgadi
Publikováno v:
Antimicrobial agents and chemotherapy. 59(1)
The effects of steady-state faldaprevir on the safety, pharmacokinetics, and pharmacodynamics of steady-state methadone and buprenorphine-naloxone were assessed in 34 healthy male and female subjects receiving stable addiction management therapy. Sub